Version history

{
  "content_md": "# Alzheimer's Disease\n\n## Overview\n\nAlzheimer's Disease (AD) represents the most prevalent neurodegenerative disorder and the leading cause of dementia globally, accounting for approximately 60-70% of all dementia cases. This progressive, irreversible condition was first documented by German psychiatrist and neuropathologist Alois Alzheimer in 1906, who identified the distinctive pathological signatures—extracellular amyloid plaques and intracellular neurofibrillary tangles—in the brain tissue of his deceased patient Auguste Deter. Today, Alzheimer's Disease affects over 50 million individuals worldwide, with prevalence increasing exponentially with age. The disease imposes enormous socio-economic burdens and represents one of the most significant challenges facing aging societies.\n\nThe pathophysiology of Alzheimer's Disease involves a complex interplay of genetic, environmental, and age-related factors that culminate in progressive neuronal dysfunction and cell death. The amyloid cascade hypothesis remains a dominant framework for understanding AD pathogenesis, proposing that the accumulation of beta-amyloid (Aβ) peptides—derived from sequential proteolytic processing of the amyloid precursor protein (APP)—initiates a toxic cascade leading to tau hyperphosphorylation, synaptic dysfunction, and eventual neurodegeneration. While this hypothesis continues to guide therapeutic development, emerging evidence suggests that the relationship between amyloid deposition and cognitive decline may be more nuanced than initially proposed.\n\nClinically, Alzheimer's Disease manifests as a gradual, progressive decline in cognitive function, typically beginning with episodic memory impairment before advancing to affect multiple domains including language, executive function, visuospatial abilities, and behavioral regulation. The disease follows a predictable staging pattern, from mild cognitive impairment through moderate dementia to severe functional dependence. Neuropathologically, AD is characterized by selective vulnerability of cholinergic neurons in the basal forebrain, hippocampus, and entorhinal cortex, with progressive spreading to broader cortical regions as the disease advances.\n\n## Capabilities/Features\n\nAlzheimer's Disease exhibits several defining pathological hallmarks at the molecular and cellular levels. The first major feature is the accumulation of extracellular amyloid plaques composed primarily of Aβ40 and Aβ42 peptides. These peptides are generated through amyloidogenic processing of APP by β-secretase (BACE1) and γ-secretase, a process that occurs predominantly in the endosomal and secretory pathways. The Aβ42 variant, with its two additional hydrophobic amino acids, demonstrates greater aggregation propensity and is the predominant species found in amyloid plaques.\n\nThe second hallmark consists of intraneuronal neurofibrillary tangles (NFTs) formed from hyperphosphorylated tau protein. Under normal conditions, tau stabilizes microtubules essential for axonal transport; however, in AD, tau becomes phosphorylated at multiple sites by kinases including GSK-3β and CDK5, leading to microtubule destabilization, tau misfolding, and aggregation into paired helical filaments. The staging of NFT pathology follows a predictable anatomical progression that correlates strongly with clinical symptom severity.\n\nBeyond plaques and tangles, Alzheimer's Disease is characterized by widespread synaptic loss, chronic neuroinflammation with activation of microglia and astrocytes, mitochondrial dysfunction, oxidative stress, and progressive neuronal death. The disease also involves widespread disruption of neural networks, with evidence of reduced functional connectivity between brain regions, particularly within the default mode network. Neurotransmitter systems are profoundly affected, with early degeneration of cholinergic neurons leading to deficits in acetylcholine signaling that have formed the basis for symptomatic treatment approaches.\n\n## Relevance to Neurodegeneration Research\n\nAlzheimer's Disease serves as a critical paradigm for understanding fundamental mechanisms of neurodegeneration, with research into AD providing insights applicable across the spectrum of neurodegenerative disorders. The disease has been instrumental in elucidating the relationships between protein misfolding, aggregation, and neuronal toxicity—a framework directly relevant to understanding pathology in [Parkinson's Disease] (α-synuclein), [Amyotrophic Lateral Sclerosis] (TDP-43, SOD1), and frontotemporal dementia (tau, FUS).\n\nDrug discovery efforts for AD have identified numerous therapeutic targets beyond amyloid, including tau phosphorylation and aggregation, neuroinflammation, mitochondrial protection, and synaptic preservation. The failure of numerous amyloid-targeting therapies in clinical trials—including monoclonal antibodies directed against Aβ—has driven substantial reconsideration of therapeutic strategies and renewed interest in multi-target approaches and earlier intervention. Biomarker research in AD, including cerebrospinal\n\n## Pathway Diagram\n\nThe following diagram shows the key molecular relationships involving ALZHEIMER discovered through SciDEX knowledge graph analysis:\n\n```mermaid\ngraph TD\n    TDC[\"TDC\"] -->|\"implicated in\"| alzheimer[\"alzheimer\"]\n    CSGA[\"CSGA\"] -->|\"implicated in\"| alzheimer[\"alzheimer\"]\n    SGMS2[\"SGMS2\"] -->|\"implicated in\"| alzheimer[\"alzheimer\"]\n    ADORA2A[\"ADORA2A\"] -->|\"implicated in\"| alzheimer[\"alzheimer\"]\n    ZO1[\"ZO1\"] -->|\"implicated in\"| alzheimer[\"alzheimer\"]\n    DDC[\"DDC\"] -->|\"implicated in\"| alzheimer[\"alzheimer\"]\n    CNO[\"CNO\"] -->|\"implicated in\"| alzheimer[\"alzheimer\"]\n    style TDC fill:#ce93d8,stroke:#333,color:#000\n    style alzheimer fill:#ef5350,stroke:#333,color:#000\n    style CSGA fill:#ce93d8,stroke:#333,color:#000\n    style SGMS2 fill:#ce93d8,stroke:#333,color:#000\n    style ADORA2A fill:#ce93d8,stroke:#333,color:#000\n    style ZO1 fill:#ce93d8,stroke:#333,color:#000\n    style DDC fill:#ce93d8,stroke:#333,color:#000\n    style CNO fill:#ce93d8,stroke:#333,color:#000\n```\n\n",
  "entity_type": "disease"
}

{
  "content_md": "# Alzheimer's Disease\n\n## Overview\n\nAlzheimer's Disease (AD) represents the most prevalent neurodegenerative disorder and the leading cause of dementia globally, accounting for approximately 60-70% of all dementia cases. This progressive, irreversible condition was first documented by German psychiatrist and neuropathologist Alois Alzheimer in 1906, who identified the distinctive pathological signatures—extracellular amyloid plaques and intracellular neurofibrillary tangles—in the brain tissue of his deceased patient Auguste Deter. Today, Alzheimer's Disease affects over 50 million individuals worldwide, with prevalence increasing exponentially with age. The disease imposes enormous socio-economic burdens and represents one of the most significant challenges facing aging societies.\n\nThe pathophysiology of Alzheimer's Disease involves a complex interplay of genetic, environmental, and age-related factors that culminate in progressive neuronal dysfunction and cell death. The amyloid cascade hypothesis remains a dominant framework for understanding AD pathogenesis, proposing that the accumulation of beta-amyloid (Aβ) peptides—derived from sequential proteolytic processing of the amyloid precursor protein (APP)—initiates a toxic cascade leading to tau hyperphosphorylation, synaptic dysfunction, and eventual neurodegeneration. While this hypothesis continues to guide therapeutic development, emerging evidence suggests that the relationship between amyloid deposition and cognitive decline may be more nuanced than initially proposed.\n\nClinically, Alzheimer's Disease manifests as a gradual, progressive decline in cognitive function, typically beginning with episodic memory impairment before advancing to affect multiple domains including language, executive function, visuospatial abilities, and behavioral regulation. The disease follows a predictable staging pattern, from mild cognitive impairment through moderate dementia to severe functional dependence. Neuropathologically, AD is characterized by selective vulnerability of cholinergic neurons in the basal forebrain, hippocampus, and entorhinal cortex, with progressive spreading to broader cortical regions as the disease advances.\n\n## Capabilities/Features\n\nAlzheimer's Disease exhibits several defining pathological hallmarks at the molecular and cellular levels. The first major feature is the accumulation of extracellular amyloid plaques composed primarily of Aβ40 and Aβ42 peptides. These peptides are generated through amyloidogenic processing of APP by β-secretase (BACE1) and γ-secretase, a process that occurs predominantly in the endosomal and secretory pathways. The Aβ42 variant, with its two additional hydrophobic amino acids, demonstrates greater aggregation propensity and is the predominant species found in amyloid plaques.\n\nThe second hallmark consists of intraneuronal neurofibrillary tangles (NFTs) formed from hyperphosphorylated tau protein. Under normal conditions, tau stabilizes microtubules essential for axonal transport; however, in AD, tau becomes phosphorylated at multiple sites by kinases including GSK-3β and CDK5, leading to microtubule destabilization, tau misfolding, and aggregation into paired helical filaments. The staging of NFT pathology follows a predictable anatomical progression that correlates strongly with clinical symptom severity.\n\nBeyond plaques and tangles, Alzheimer's Disease is characterized by widespread synaptic loss, chronic neuroinflammation with activation of microglia and astrocytes, mitochondrial dysfunction, oxidative stress, and progressive neuronal death. The disease also involves widespread disruption of neural networks, with evidence of reduced functional connectivity between brain regions, particularly within the default mode network. Neurotransmitter systems are profoundly affected, with early degeneration of cholinergic neurons leading to deficits in acetylcholine signaling that have formed the basis for symptomatic treatment approaches.\n\n## Relevance to Neurodegeneration Research\n\nAlzheimer's Disease serves as a critical paradigm for understanding fundamental mechanisms of neurodegeneration, with research into AD providing insights applicable across the spectrum of neurodegenerative disorders. The disease has been instrumental in elucidating the relationships between protein misfolding, aggregation, and neuronal toxicity—a framework directly relevant to understanding pathology in [Parkinson's Disease] (α-synuclein), [Amyotrophic Lateral Sclerosis] (TDP-43, SOD1), and frontotemporal dementia (tau, FUS).\n\nDrug discovery efforts for AD have identified numerous therapeutic targets beyond amyloid, including tau phosphorylation and aggregation, neuroinflammation, mitochondrial protection, and synaptic preservation. The failure of numerous amyloid-targeting therapies in clinical trials—including monoclonal antibodies directed against Aβ—has driven substantial reconsideration of therapeutic strategies and renewed interest in multi-target approaches and earlier intervention. Biomarker research in AD, including cerebrospinal\n\n## Pathway Diagram\n\nThe following diagram shows the key molecular relationships involving ALZHEIMER discovered through SciDEX knowledge graph analysis:\n\n```mermaid\ngraph TD\n    TDC[\"TDC\"] -->|\"implicated in\"| alzheimer[\"alzheimer\"]\n    CSGA[\"CSGA\"] -->|\"implicated in\"| alzheimer[\"alzheimer\"]\n    SGMS2[\"SGMS2\"] -->|\"implicated in\"| alzheimer[\"alzheimer\"]\n    ADORA2A[\"ADORA2A\"] -->|\"implicated in\"| alzheimer[\"alzheimer\"]\n    ZO1[\"ZO1\"] -->|\"implicated in\"| alzheimer[\"alzheimer\"]\n    DDC[\"DDC\"] -->|\"implicated in\"| alzheimer[\"alzheimer\"]\n    CNO[\"CNO\"] -->|\"implicated in\"| alzheimer[\"alzheimer\"]\n    style TDC fill:#ce93d8,stroke:#333,color:#000\n    style alzheimer fill:#ef5350,stroke:#333,color:#000\n    style CSGA fill:#ce93d8,stroke:#333,color:#000\n    style SGMS2 fill:#ce93d8,stroke:#333,color:#000\n    style ADORA2A fill:#ce93d8,stroke:#333,color:#000\n    style ZO1 fill:#ce93d8,stroke:#333,color:#000\n    style DDC fill:#ce93d8,stroke:#333,color:#000\n    style CNO fill:#ce93d8,stroke:#333,color:#000\n```\n\n",
  "entity_type": "disease"
}

{
  "content_md": "# Alzheimer's Disease\n\n## Overview\n\nAlzheimer's Disease (AD) represents the most prevalent neurodegenerative disorder and the leading cause of dementia globally, accounting for approximately 60-70% of all dementia cases. This progressive, irreversible condition was first documented by German psychiatrist and neuropathologist Alois Alzheimer in 1906, who identified the distinctive pathological signatures—extracellular amyloid plaques and intracellular neurofibrillary tangles—in the brain tissue of his deceased patient Auguste Deter. Today, Alzheimer's Disease affects over 50 million individuals worldwide, with prevalence increasing exponentially with age. The disease imposes enormous socio-economic burdens and represents one of the most significant challenges facing aging societies.\n\nThe pathophysiology of Alzheimer's Disease involves a complex interplay of genetic, environmental, and age-related factors that culminate in progressive neuronal dysfunction and cell death. The amyloid cascade hypothesis remains a dominant framework for understanding AD pathogenesis, proposing that the accumulation of beta-amyloid (Aβ) peptides—derived from sequential proteolytic processing of the amyloid precursor protein (APP)—initiates a toxic cascade leading to tau hyperphosphorylation, synaptic dysfunction, and eventual neurodegeneration. While this hypothesis continues to guide therapeutic development, emerging evidence suggests that the relationship between amyloid deposition and cognitive decline may be more nuanced than initially proposed.\n\nClinically, Alzheimer's Disease manifests as a gradual, progressive decline in cognitive function, typically beginning with episodic memory impairment before advancing to affect multiple domains including language, executive function, visuospatial abilities, and behavioral regulation. The disease follows a predictable staging pattern, from mild cognitive impairment through moderate dementia to severe functional dependence. Neuropathologically, AD is characterized by selective vulnerability of cholinergic neurons in the basal forebrain, hippocampus, and entorhinal cortex, with progressive spreading to broader cortical regions as the disease advances.\n\n## Capabilities/Features\n\nAlzheimer's Disease exhibits several defining pathological hallmarks at the molecular and cellular levels. The first major feature is the accumulation of extracellular amyloid plaques composed primarily of Aβ40 and Aβ42 peptides. These peptides are generated through amyloidogenic processing of APP by β-secretase (BACE1) and γ-secretase, a process that occurs predominantly in the endosomal and secretory pathways. The Aβ42 variant, with its two additional hydrophobic amino acids, demonstrates greater aggregation propensity and is the predominant species found in amyloid plaques.\n\nThe second hallmark consists of intraneuronal neurofibrillary tangles (NFTs) formed from hyperphosphorylated tau protein. Under normal conditions, tau stabilizes microtubules essential for axonal transport; however, in AD, tau becomes phosphorylated at multiple sites by kinases including GSK-3β and CDK5, leading to microtubule destabilization, tau misfolding, and aggregation into paired helical filaments. The staging of NFT pathology follows a predictable anatomical progression that correlates strongly with clinical symptom severity.\n\nBeyond plaques and tangles, Alzheimer's Disease is characterized by widespread synaptic loss, chronic neuroinflammation with activation of microglia and astrocytes, mitochondrial dysfunction, oxidative stress, and progressive neuronal death. The disease also involves widespread disruption of neural networks, with evidence of reduced functional connectivity between brain regions, particularly within the default mode network. Neurotransmitter systems are profoundly affected, with early degeneration of cholinergic neurons leading to deficits in acetylcholine signaling that have formed the basis for symptomatic treatment approaches.\n\n## Relevance to Neurodegeneration Research\n\nAlzheimer's Disease serves as a critical paradigm for understanding fundamental mechanisms of neurodegeneration, with research into AD providing insights applicable across the spectrum of neurodegenerative disorders. The disease has been instrumental in elucidating the relationships between protein misfolding, aggregation, and neuronal toxicity—a framework directly relevant to understanding pathology in [Parkinson's Disease] (α-synuclein), [Amyotrophic Lateral Sclerosis] (TDP-43, SOD1), and frontotemporal dementia (tau, FUS).\n\nDrug discovery efforts for AD have identified numerous therapeutic targets beyond amyloid, including tau phosphorylation and aggregation, neuroinflammation, mitochondrial protection, and synaptic preservation. The failure of numerous amyloid-targeting therapies in clinical trials—including monoclonal antibodies directed against Aβ—has driven substantial reconsideration of therapeutic strategies and renewed interest in multi-target approaches and earlier intervention. Biomarker research in AD, including cerebrospinal",
  "entity_type": "disease"
}

{
  "content_md": "# Alzheimer's Disease\n\n## Overview\n\nAlzheimer's Disease (AD) is a progressive, irreversible neurodegenerative disorder that represents the most common cause of dementia worldwide, accounting for approximately 60-70% of all dementia cases. The disease was first described by German psychiatrist and neuropathologist Alois Alzheimer in 1906, who observed distinctive pathological hallmarks—amyloid plaques and neurofibrillary tangles—in the brain tissue of his deceased patient Auguste Deter. Today, Alzheimer's Disease affects an estimated 50 million people globally, with prevalence projected to triple by 2050 due to aging populations, making it one of the most significant healthcare challenges of the 21st century.\n\nClinically, Alzheimer's Disease manifests as a gradual decline in cognitive function, typically beginning with episodic memory impairment and progressing to affect language, reasoning, visuospatial abilities, and executive function. The disease follows a characteristic trajectory from mild cognitive impairment (MCI) to moderate and severe dementia, with patients eventually becoming dependent on others for basic activities of daily living. The average survival time from diagnosis ranges from 4 to 8 years, though this can vary significantly based on age at onset and other factors. Beyond the cognitive symptoms, patients often experience behavioral and psychological symptoms including depression, anxiety, agitation, and sleep disturbances.\n\nThe neuropathological signatures of Alzheimer's Disease include extracellular amyloid plaques composed of aggregated amyloid-beta (Aβ) peptides and intracellular neurofibrillary tangles (NFTs) formed from hyperphosphorylated tau protein. These pathological changes begin accumulating years, even decades, before clinical symptoms appear, reflecting a lengthy preclinical phase. The disease mechanism involves a complex interplay between amyloid accumulation, tau pathology, neuroinflammation, synaptic dysfunction, and neuronal loss, particularly affecting cholinergic neurons in the basal forebrain and memory-critical regions including the hippocampus and entorhinal cortex.\n\n## Capabilities/Features\n\nAlzheimer's Disease exhibits several distinctive pathophysiological features that define its progression and clinical manifestations. The amyloid cascade hypothesis posits that the accumulation of amyloid-beta peptides, particularly the aggregation-prone Aβ42 isoform, represents the initiating event in disease pathogenesis. These peptides are generated through proteolytic processing of the amyloid precursor protein (APP) by beta-secretase (BACE1) and gamma-secretase enzymes, with pathogenic mutations in APP and the presenilin (PSEN1, PSEN2) components of gamma-secretase causing familial early-onset forms of the disease.\n\nThe tau protein, a microtubule-associated protein that stabilizes neuronal cytoskeletons, undergoes abnormal hyperphosphorylation in Alzheimer's Disease, leading to its dissociation from microtubules and aggregation into paired helical filaments that form neurofibrillary tangles. This tau pathology spreads in a characteristic pattern that correlates with clinical progression, beginning in the entorhinal cortex and spreading to the hippocampus and eventually throughout the neocortex. The prion-like spreading of pathological tau between neurons has become a major focus of research, revealing templated conversion mechanisms similar to those observed in other neurodegenerative conditions.\n\nGenetic risk factors play a significant role in Alzheimer's Disease susceptibility. The apolipoprotein E (APOE) ε4 allele represents the strongest genetic risk factor for late-onset sporadic AD, approximately tripling the risk compared to the common ε3 allele. In contrast, mutations in APP, PSEN1, and PSEN2 cause autosomal dominant forms of early-onset familial AD. Recent genome-wide association studies have identified over 40 genetic risk loci, many implicating immune function, lipid metabolism, and endosomal vesicle trafficking pathways.\n\nNeurotransmitter systems undergo progressive degeneration in Alzheimer's Disease, with particular impact on the cholinergic system. Basal forebrain cholinergic neurons, which project to the hippocampus and ne",
  "entity_type": "disease"
}

{
  "content_md": "# Alzheimer's Disease\n\n## Overview\n\nAlzheimer's Disease (AD) is a progressive, irreversible neurodegenerative disorder that represents the most common cause of dementia worldwide, accounting for approximately 60-70% of all dementia cases. The disease was first described by German psychiatrist and neuropathologist Alois Alzheimer in 1906, who observed distinctive pathological hallmarks—amyloid plaques and neurofibrillary tangles—in the brain tissue of his deceased patient Auguste Deter. Today, Alzheimer's Disease affects an estimated 50 million individuals globally, with prevalence projected to triple by 2050 as populations age.\n\nThe disease manifests through a gradual decline in cognitive function, initially affecting episodic memory and progressively compromising language, reasoning, and executive function. Pathophysiologically, Alzheimer's Disease is characterized by the accumulation of amyloid-beta (Aβ) plaques in extracellular spaces and the intracellular formation of neurofibrillary tangles composed of hyperphosphorylated tau protein. These pathological processes trigger a cascade of neurotoxic events, including synaptic dysfunction, neuroinflammation, and ultimately neuronal death, particularly in brain regions critical for memory and cognition such as the hippocampus and entorhinal cortex.\n\n## Capabilities/Features\n\nAlzheimer's Disease exhibits several defining molecular and clinical features that distinguish it from other neurodegenerative conditions:\n\n**Amyloid Processing and Plaque Formation**: The amyloid cascade hypothesis posits that the sequential proteolytic cleavage of amyloid precursor protein (APP) by β-secretase (BACE1) and γ-secretase generates amyloid-beta peptides, predominantly Aβ40 and Aβ42. These hydrophobic peptides aggregate into oligomers, fibrils, and eventually insoluble plaques that disrupt synaptic function and trigger inflammatory responses.\n\n**Tau Pathology and Neurofibrillary Tangles**: The microtubule-associated protein tau undergoes aberrant hyperphosphorylation in Alzheimer's Disease, causing its dissociation from microtubules and aggregation into paired helical filaments. These aggregates form neurofibrillary tangles that destabilize neuronal cytoskeleton and contribute to axonal transport dysfunction.\n\n**Neuroinflammation and Glial Activation**: Microglial cells become chronically activated in AD brains, releasing pro-inflammatory cytokines including IL-1β, TNF-α, and IL-6. Astrocytes undergo reactive changes that compromise their supportive functions. This neuroinflammatory environment accelerates neurodegeneration and may be driven by complement system activation.\n\n**Genetic Risk Factors**: Early-onset familial AD (FAD) is caused by autosomal dominant mutations in APP, PSEN1, or PSEN2 genes. Late-onset sporadic AD involves complex polygenic susceptibility, with the ε4 allele of apolipoprotein E (APOE4) representing the strongest known genetic risk factor, approximately 3-4 times increasing disease risk.\n\n## Relevance to Neurodegeneration Research\n\nAlzheimer's Disease serves as a central paradigm in neurodegeneration research, providing insights applicable to understanding other proteinopathies. The disease's relationship with [Senescence] phenotypes highlights how cellular aging processes contribute to neurodegenerative vulnerability. Research demonstrates that senescent astrocytes and microglia accumulate in AD brains, secreting inflammatory factors that propagate neuronal damage.\n\nThe intersection between Alzheimer's Disease and [Amyotrophic Lateral Sclerosis] (ALS) reveals shared molecular mechanisms, including protein aggregation, oxidative stress, and mitochondrial dysfunction. Transcriptomic studies identify overlapping gene expression changes in both conditions, suggesting convergent pathogenic pathways.\n\nThe [Complement] system activation observed in AD connects neuroinflammation to synaptic loss. Complement components C1q and C3 are upregulated around amyloid plaques, mediating microglial phagocytosis of synapses—a process termed \"synaptic stripping\" that correlates with cognitive decline. This pathway represents a promising therapeutic target for preserving neuronal connectivity.\n\nAD research also informs understanding of protein aggregation in [Parkinson's Disease], where α-synuclein forms Lewy bodies similarly to tau and Aβ assemblies. Common therapeutic strategies targeting protein clearance, including immunotherapies and autophagy modulation, are being investigated across multiple neurodegenerative conditions.\n\n## Related Entities\n\n- [Amyloid-beta] - The primary component of extracellular plaques\n- [Tau Protein] - Forms neurofibrillary tangles when hyperphosphorylated\n- [Apolipoprotein E] - Major genetic risk factor, particularly the APOE4 isoform\n- [Complement System] - Mediates neuroinflammatory synaptic loss\n- [Senescence] - Cellular aging contributes to AD pathogenesis\n- [Amyotrophic Lateral Sclerosis] - Shares overlapping molecular mechanisms with AD\n- [Parkinson's Disease] - Another proteinopathy with overlapping research approaches\n- [Microglial Cells] - Key drivers of neuroinflammation in AD\n\n## References\n\n- Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016.\n- Scheltens P, et al. Alzheimer's disease. Lancet. 2021.\n- Long JM, Bhagat HA. Alzheimer Disease: An Update. Am J Med. 2022.\n- Hampel H, et al. The Amyloid-β clearance as a target for Alzheimer's disease therapy. Trends Neurosci. 2021.",
  "entity_type": "disease"
}

{
  "content_md": "A disease referenced in 15305 knowledge graph relationships. Key connections: activates Complement, associated_with Senescence, associated_with Amyotrophic Lateral Sclerosis. Associated with 5 hypothesiss in the SciDEX knowledge base.",
  "entity_type": "disease"
}